ECONSALUT

Critical comments on health economics and policy

30 d’agost 2022

Precision medicine (2)

›
 Advancing Healthcare Through Personalized Medicine
25 d’agost 2022

AI everywhere (16)

›
 The Doctor and the Algorithm. Promise, Peril, and the Future of Health AI AI is a clear and present danger to health, safety, and equity. A...
18 d’agost 2022

Health reform zombies (3)

›
 Health Reform Without Side Effects: Making Markets Work for Individual Health Insurance
17 d’agost 2022

Pandemethics (2)

›
 Pandemic Bioethics Contents: Chapter 1 Historical Epidemics The Spanish Flu of 1918 Cholera Plague Smallpox Yellow Fever Malaria Chapter 2 ...
13 d’agost 2022

Decentralization in healthcare

›
 Federalism and Decentralization in Health Care. A Decision Space Approach
12 d’agost 2022

The ableist conflation

›
 The Life Worth Living. Disability, Pain, and Morality The central argument of this book can be stated simply: the canonical idea that some ...
10 d’agost 2022

Do no harm

›
 Ante todo no hagas daño
02 d’agost 2022

Can capitalism be reimagined ?(5)

›
  Woke Capitalism. How Corporate Morality is Sabotaging Democracy The Oxford dictionary’s definition woke refers to being ‘well informed’ or...
29 de juliol 2022

Against patents, again (3)

›
 Patent Politics. Life Forms, Markets, and the Public Interest in the United States and Europe Comparing battles over patents on animals, hu...
28 de juliol 2022

Against patents (2)

›
 Medical Monopoly. Intellectual Property Rights and the Origins of the Modern Pharmaceutical Industry Medical Monopoly combines legal, medic...
25 de juliol 2022

On epigenetics and health (2)

›
 The Epigenetics Revolution. How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance The ‘epi’ in epigenetic...
20 de juliol 2022

Covid-19 response

›
 Covid-19. La respuesta autoritaria y la estrategia del miedo
14 de juliol 2022

Pharma, big pharma (14)

›
 Global Pharmaceutical Policy
13 de juliol 2022

Pharma, big pharma (13)

›
 Studies on Competition and Antitrust Issues in the Pharmaceutical Industry
‹
›
Inici
Visualitza la versió per a web
Pere Ibern
Visualitza el meu perfil complet
Amb la tecnologia de Blogger.